Abbott Laboratories Announces Consideration for Debt Tender Offers

ABBOTT PARK, Ill., Nov. 8, 2012 /PRNewswire/ -- Abbott (ABT) announced today the reference yield and the total consideration for the nine series of notes subject to the previously announced tender offers (the "Tender Offers") to purchase for cash (i) any and all of its outstanding 4.35% Notes due March 2014 (the "2014 Notes"), 2.70% Notes due May 2015 (the "2015 Notes"), 5.875% Notes due May 2016 (the "2016 Notes") and 5.60% Notes due November 2017 (the "2017 Notes" and, collectively with the 2014 Notes, the 2015 Notes and the 2016 Notes, the "Any and All Notes," and such offers, the "Any and All Offers") and (ii) up to an aggregate principal amount equal to the applicable Series Tender Cap (as defined in the table below) of its 5.125% Notes due April 2019 (the "2019 Notes"), 4.125% Notes due May 2020 (the "2020 Notes"), 6.15% Notes due November 2037 (the "2037 Notes"), 6.00% Notes due April 2039 (the "2039 Notes") and 5.300% Notes due May 2040 (the "2040 Notes" and, collectively with the 2019 Notes, the 2020 Notes, the 2037 Notes and the 2039 Notes, the "Partial Offer Notes," and such offers, the "Partial Offers"). The Partial Offer Notes, collectively with the Any and All Notes, are referred to as "Notes," and each is referred to as a "Series" of Notes.